Valuation: Genmab A/S

Market Cap 221B 33.12B 29.57B 27.13B 24.68B 46.27B 3,135B 47.19B 324B 131B 1,655B 124B 122B 5,227B P/E 2026 *
44.7x
P/E 2027 * 31x
Enterprise Value 241B 36.09B 32.22B 29.57B 26.9B 50.43B 3,417B 51.43B 353B 142B 1,803B 135B 133B 5,696B EV / Sales 2026 *
7.99x
EV / Sales 2027 * 6.43x
Free-Float
94.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Genmab A/S

1 day+0.14%
1 week+23.72%
Current month-5.21%
1 month+55.99%
3 months+100.87%
6 months+117.16%
Current year+82.93%
1 week 2,975
Extreme 2975
3,947
1 month 2,310
Extreme 2310
3,947
Current year 1,512
Extreme 1512
3,947
1 year 1,512
Extreme 1512
3,947
3 years 1,157
Extreme 1157
3,947
5 years 1,157
Extreme 1157
3,947
10 years 786.2
Extreme 786.2
3,947
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2010
Director of Finance/CFO 48 01/03/2020
Chief Tech/Sci/R&D Officer - 16/08/2024
Director TitleAgeSince
Director/Board Member 75 01/11/2003
Director/Board Member 58 01/01/2015
Director/Board Member 75 01/01/2015
Date Insider Type Main position Quantity % Market Cap. Importance
12/1/25 A Exercice

Director

189 0.0003%
12/1/25 A Exercice

Director

189 0.0003%
12/1/25 A Exercice

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+0.14%+23.72%+98.87%+83.56% 33.12B
-2.37%-5.03%+39.49%+62.39% 62.23B
-0.08%+0.08%+10.37%+68.26% 54.92B
-0.25%+1.51%+19.70%+96.11% 55.26B
-3.33%-5.54%+19.39%+35.69% 42.59B
-2.45%-2.59%+16.36%+98.45% 41.08B
-1.64%+2.32%+219.80%+789.69% 40.33B
+0.21%+1.05%+14.81%+46.96% 32.61B
-2.90%+17.12%-42.35%+337.07% 23.98B
-3.45%-3.58%+20.89%-10.20% 23.33B
Average -1.14%+3.56%+41.73%+160.80% 40.94B
Weighted average by Cap. -1.24%+2.43%+43.25%+152.65%

Financials

2026 *2027 *
Net sales 30.14B 4.52B 4.03B 3.7B 3.37B 6.31B 428B 6.44B 44.2B 17.82B 226B 16.95B 16.59B 713B 36.23B 5.43B 4.85B 4.45B 4.05B 7.59B 514B 7.74B 53.13B 21.42B 271B 20.38B 19.94B 857B
Net income 5.14B 770M 687M 631M 574M 1.08B 72.9B 1.1B 7.53B 3.04B 38.48B 2.89B 2.83B 122B 7.58B 1.14B 1.01B 931M 847M 1.59B 108B 1.62B 11.12B 4.48B 56.79B 4.27B 4.17B 179B
Net Debt 19.85B 2.97B 2.66B 2.44B 2.22B 4.16B 282B 4.24B 29.11B 11.73B 149B 11.16B 10.93B 469B 11.9B 1.78B 1.59B 1.46B 1.33B 2.49B 169B 2.54B 17.45B 7.03B 89.09B 6.69B 6.55B 281B
Projected Income Statement - Annual - Genmab A/S
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,119
Date Price Change Volume
03/11/26 DKK 3,708.00 +0.27% 65,657
02/11/26 DKK 3,698.00 -5.47% 271,367
30/10/26 DKK 3,912.00 +3.27% 234,914
29/10/26 DKK 3,788.00 -2.07% 453,954
28/10/26 DKK 3,868.00 +29.06% 800,296
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Genmab A/S
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
3,698.00DKK
Average target price
4,003.15DKK
Spread / Average Target
+8.25%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Genmab A/S
  1. Stock Market
  2. Stocks
  3. GMAB Stock